ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases. Through proprietary manufacturing processes, ImmuCell delivers bioactive immunoglobulins and immune-supporting factors to strengthen the health and survivability of young ruminants.

In addition to its passive immunology franchise, ImmuCell provides veterinary diagnostic assays and treatment products targeting common cattle diseases. Its in-house laboratory services encompass immunodiagnostic tests and therapeutic interventions aimed at improving udder health and controlling infectious conditions within herds across North America.

Since its founding, ImmuCell has cultivated partnerships with animal health professionals, distributors, and research organizations to expand its reach throughout the United States and into select international markets. The company is led by a management team with expertise in veterinary science, agriculture, and commercial operations, positioning it to advance innovative solutions for livestock producers worldwide.

Key Stats

• Today's Range: $6.08 to $6.16
• 50-Day Range: $5.65 to $6.80
• 52-Week Range: $3.38 to $7.60
• Volume: 11,053 shs
• Average Volume: 23,408 shs
• Market Capitalization: $55.00 million
• P/E Ratio: 32.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ImmuCell Stock Analysis - MarketRank™

ImmuCell scored higher than 21% of companies evaluated by MarketBeat, and ranked 902nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ImmuCell.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmuCell is 32.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmuCell is 32.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.46.

Price to Book Value per Share Ratio

ImmuCell has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently decreased by 5.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmuCell does not currently pay a dividend.

Dividend Growth

ImmuCell does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.17% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently decreased by 5.66%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.95

News Sentiment

ImmuCell has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for ImmuCell this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added ImmuCell to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmuCell insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.60% of the stock of ImmuCell is held by insiders.

Percentage Held by Institutions

Only 13.47% of the stock of ImmuCell is held by institutions.

ICCC Stock Analysis - Frequently Asked Questions

How have ICCC shares performed this year?

ImmuCell's stock was trading at $5.15 at the start of the year. Since then, ICCC shares have increased by 18.1% and is now trading at $6.08.

How were ImmuCell's earnings last quarter?

ImmuCell Corporation (NASDAQ:ICCC) posted its earnings results on Thursday, August, 14th. The biotechnology company reported $0.06 EPS for the quarter. The biotechnology company earned $6.45 million during the quarter. ImmuCell had a net margin of 6.23% and a trailing twelve-month return on equity of 6.25%.
Read the conference call transcript.

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/25/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 70
• Year Founded: 1982

Profitability

• EPS (Trailing Twelve Months): $0.19
• Trailing P/E Ratio: 32.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.16 million
• Net Margins: 6.23%
• Pretax Margin: 6.27%
• Return on Equity: 6.25%
• Return on Assets: 3.87%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 3.85
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $28.27 million
• Price / Sales: 1.95
• Cash Flow: $0.06 per share
• Price / Cash Flow: 94.25
• Book Value: $3.09 per share
• Price / Book: 1.97

Miscellaneous

• Outstanding Shares: 9,046,000
• Free Float: 8,539,000
• Market Cap: $55.00 million
• Optionable: Not Optionable
• Beta: 0.30